| 28.3 1.53 (5.72%) | 05-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 35.49 |
1-year : | 41.45 |
| Resists | First : | 30.38 |
Second : | 35.49 |
| Pivot price | 26.5 |
|||
| Supports | First : | 26.38 |
Second : | 23.9 |
| MAs | MA(5) : | 26.69 |
MA(20) : | 26.34 |
| MA(100) : | 41  |
MA(250) : | 46.16 |
|
| MACD | MACD : | -1.4 |
Signal : | -2.1 |
| %K %D | K(14,3) : | 81.9 |
D(3) : | 66.9 |
| RSI | RSI(14): 49.8 |
|||
| 52-week | High : | 63.58 | Low : | 23.9 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AZTA ] has closed It is unclear right now based on current values. 57.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 28.99 - 29.19 | 29.19 - 29.35 |
| Low: | 27.66 - 27.88 | 27.88 - 28.04 |
| Close: | 28.02 - 28.35 | 28.35 - 28.61 |
Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.
Sun, 11 May 2025
Azenta to Participate in the UBS MedTech, Tools and Genomics Summit 2023 - Seeking Alpha
Fri, 09 May 2025
AZTA Q1 Earnings Call: Revenue Tops Expectations, Margin Progress Amid Macro Headwinds - FinancialContent
Thu, 08 May 2025
Azenta, Inc. (NASDAQ:AZTA) Q2 2025 Earnings Call Transcript - Insider Monkey
Thu, 08 May 2025
Azenta Inc (AZTA) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Macroeconomic ... - Yahoo
Wed, 07 May 2025
Azenta (AZTA) Price Target Lowered by Needham to $40 | AZTA Stock News - GuruFocus
Wed, 07 May 2025
Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025 - Quantisnow
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 46 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 1.6 (%) |
| Held by Institutions | 113.5 (%) |
| Shares Short | 4,910 (K) |
| Shares Short P.Month | 4,350 (K) |
| EPS | -0.98 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 37.16 |
| Profit Margin | -9.8 % |
| Operating Margin | -8.8 % |
| Return on Assets (ttm) | -1.7 % |
| Return on Equity (ttm) | -8.6 % |
| Qtrly Rev. Growth | -9.9 % |
| Gross Profit (p.s.) | 6.1 |
| Sales Per Share | 14.61 |
| EBITDA (p.s.) | 0.38 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 72 (M) |
| Levered Free Cash Flow | 41 (M) |
| PE Ratio | -29.18 |
| PEG Ratio | 0 |
| Price to Book value | 0.76 |
| Price to Sales | 1.93 |
| Price to Cash Flow | 17.96 |
| Dividend | 0.1 |
| Forward Dividend | 0 |
| Dividend Yield | 0.3% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|